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ORIGINAL RESEARCH
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ME, 7Tufts University, Boston, MA, 8Geisinger Commonwealth School of Medicine, Center for Pharmacy Innovation &
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Introduction:

The Diversion Alert Program (DAP) was established to curb misuse of drugs and help identify people
who may need treatment for substance use disorder (SUD). Law enforcement compiled arrest data
into a database accessible by health care providers. Our objectives were to identify regional and
demographic differences in drug use and misuse in Maine.

Methods:

All arrests (N = 11 234) reported to the DAP from 2013 to 2018 were examined by county and arrestee
demographics, and classified into families (opioids, stimulants, sedatives). The Drug Enforcement
Administration’s Automation of Reports and Consolidated Orders System (ARCOS) tracks the
distribution of controlled pharmaceuticals (Schedule II-III). Opioids were converted to oral morphine
milligram equivalents (MMEs). County and zip-code maps were constructed.

Results:

The most arrests per capita occurred in Androscoggin, Knox, and Cumberland Counties. Opioids were
the most common drug class in arrests in all counties except Aroostook County, where stimulants
were most common. Medical distribution of opioids varied. Although buprenorphine doubled, many
prescription opioids (eg, hydrocodone, fentanyl, oxymorphone) exhibited large (> 50%) reductions in
distribution. Methadone was the predominant opioid statewide (56.4% of total MMEs), although there
were sizable differences between regions (Presque Isle = 8.6%, Bangor = 78.9%). Amphetamine
distribution increased by 67.9%.

Discussion:

The DAP, a unique pharmacoepidemiological resource, revealed a 6-fold difference in drug arrests
by county. Regional differences in methadone may be due to heterogeneities in methadone clinic
distribution.

Conclusions:

The decrease in most prescription opioids, but increase in prescription stimulants, may warrant
continued monitoring to improve public health.

Keywords:

demographic differences, arrests, Maine, opioids, stimulants

I

n the New England states, the morphine milligram
equivalents (MMEs) prescribed per person were
among the highest in the United States. In 2016,
Maine was ranked fifth nationally at 1393 MME,
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which increased to 2000 MME when opioid use
disorder (OUD) medications, buprenorphine and
methadone, were included.1 Importantly, more
than 80% of people who use heroin started with
prescription opioids.2 Over the past 2 decades,
opioid prescribing patterns differed appreciably
in the United States. In states such as Maine,
West Virginia, Kentucky, prescribing rates in the
late 1990s were 2.5 to 5.0 times higher than the
national average for hydrocodone and oxycodone.3
1
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States with a higher median age, such as Maine,
also used more prescription opioids in general.1
Cumberland County, containing Maine’s largest city
of Portland, accounted for 60% more drug-related
deaths from 1997 to 2002 than would be anticipated
based on the population. This percentage indicates
an ongoing issue that has been plaguing the region.
Based on Maine’s medical examiner reports,
methadone, oxycodone, fentanyl, hydrocodone,
and other prescription opioids were the drugs most
often mentioned on death certificates in the last 2
decades.4 Drug fatalities in years as recent as 2019
continued to involve opioids in 84% of the cases.
These fatal overdoses typically occurred with other
substances, including fentanyl analogs, which have
been on the rise since 2013.5,6 Innovative strategies
are needed to address this ongoing public health
crisis.
Maine had a novel database, the Diversion Alert
Program (DAP), which originated in Aroostook
County and was expanded statewide to improve
communication between law enforcement and
health care providers. The DAP included arrestee
names, dates of birth, towns of residence, drug
charges, implicated drugs, and arresting agency
for adults whose arrest involved illicit substances,
prescription medications, and non-prescription
pharmaceuticals.7 As a point-of-care tool, this
resource could be used to help identify patients who
might have needed specialist (eg, pain, psychiatry,
or addiction medicine) involvement. The DAP was
also used as a pharmacoepidemiological source,
with regular reports for 2014 through 2017.3,5,7,8,9 The
predominant substances involved in arrests were
heroin, cocaine and crack cocaine, buprenorphine,
oxycodone,
methamphetamine,
alprazolam,
clonazepam, marijuana, hydrocodone, fentanyl,
amphetamine, α-pyrrolidinovalerophenone (or bath
salts), and gabapentin. Possession accounted for
most (three-fifths) charges, followed by trafficking.
Older adults (≥ 60 years old) had a significant
and disproportionate percentage of their arrests
involving oxycodone and hydrocodone.8 The annual
reports showed that Cumberland and Androscoggin
Counties led the state on population-corrected
arrests.7,8
The first objective of this study was to analyze
nonmedical use of controlled substances at a
county level as reported by the DAP. The second
objective was to examine whether the arrest profile
differed by arrestee demographics, specifically
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their biological sex and age. The third objective
was to use a comprehensive data source, the Drug
Enforcement Administration’s (DEA) Automation
of Reports and Consolidated Ordering System
(ARCOS) to determine regional changes in medical
use of controlled substances in Maine. Collectively,
we aimed to identify which recreational and medical
drugs and drug classes are of concern, and to reveal
the demographic and regional profile of those at risk
for substance misuse in Maine.

METHODS
Procedures
Two complementary data sources were used: the
DAP and ARCOS. The sample included all arrests
(N = 11 234) reported to the DAP from 2013, when
the program expanded statewide, to March 2018,
when the program ceased operation due to lack of
funding. Local, state, and federal law enforcement
agencies provided information. A de-identified
spreadsheet containing information on age, sex,
county of arrest (Supplemental Figure 1), substance,
and offense was obtained. A prior study determined
that, overall, possession accounted for 60.0% of
arrests, followed by trafficking (24.5%), distribution
(3.9%), and possession with intent to distribute
(3.5%); however, this general pattern differed
considerably by agent.9 Arrest data was classified
by the arrestee’s county of residence. State and
county values were calculated for the following
categories: total number of arrests, total population,
percentage of county population arrested,
percentage of arrests involving females, mean
age of total arrests, percentage of arrests involving
opioids or stimulants, most frequent federal drug
schedule, and most common level (federal, state,
county, or city) of arresting agency. For simplicity,
county and city agencies are henceforth designated
as “local.” Additional information, including the
processing steps for arrests involving multiple
drugs, is available elsewhere.7
The DEA’s ARCOS is a federal program created with
the 1970 Controlled Substances Act that collects
data (weight distributed in grams) of Schedule
II and III substances distributed to pharmacies,
hospitals, methadone treatment programs (referred
to by the DEA as narcotic treatment programs),
and providers.10 From 2008 to 2017, the program
evaluated 13 opioid pain medications (oxycodone,
fentanyl, morphine, hydrocodone, hydromorphone,
oxymorphone, tapentadol, codeine, meperidine,
2
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dihydrocodeine, sufentanil, remifentanil, and
alfentanil), and 2 opioids used primarily for OUD
(methadone and buprenorphine). The oral MME
conversion factors (eg, tapentadol = 0.4, methadone
= 10) are available elsewhere.3 The weights
distributed of stimulants (eg, methylphenidate,
amphetamines, lisdexamfetamine) and barbiturates
(eg, pentobarbital, secobarbital) were also obtained.
ARCOS was previously validated by comparing
results for a single opioid with that obtained for
the Maine Prescription Monitoring Program, which
revealed a high correlation (r = 0.985).1 Similarly,
when classifying areas into high versus low
stimulant use, ARCOS showed a high agreement
(96.4%) with the California Prescription Monitoring
Program.11 Procedures were approved by the ethics
committee of the University of New England.
Data analysis
The rate of arrests per county was determined
by taking the total number of arrests by the years
DAP was operational statewide (4.75), dividing that
number by the population in 2015 (ie, the midpoint
year)11, and multiplying that value by ten-thousand.
Maine’s population increased by 1.3% from 2008
to 2017. The percentage of all arrests involving
females was calculated by dividing the number of
female arrestees by the total number of arrests for
each county. The percentage of arrests involving
opioids or stimulants were calculated by dividing
the number of arrests involving each drug class by
the number of arrests in the county. ARCOS also
reports drug distribution by the first 3 digits of the zip
code. For simplicity, 039 = York, 040 = Kennebunk,
041 = Portland, 042 = Lewiston, 043 = Augusta,
044 = Bangor, 045 = Boothbay Harbor, 046 = Bar
Harbor, 047 = Presque Isle, 048 = Rockport, and
049 = Waterville. Geographic differences in the total
MME for each opioid were expressed by dividing
the highest percentages by the lowest percentages
based on area (eg, 50% in county A/10% in county
B = a 5-fold difference). The locations of the
methadone clinics were obtained (August 2020).
Relative to their peak year, arbitrary categories
were interpreted as small (0% to 19.9%), medium
(20.0% to 49.9%), and large (≥ 50.0%) changes in
controlled substance weight per year. County maps
were generated with Microsoft Excel and QGIS.

RESULTS
Diversion Alert Program
Between 2013 and 2018, a total of 11 234 drugrelated arrests were reported to the DAP. A 5.6Published by MaineHealth Knowledge Connection, 2021

fold difference in the rate of arrests, corrected
for population, occurred in Androscoggin County
(26.9) relative to Piscataquis County (4.8). In
Androscoggin County, 35.2% of the arrested
population was female, compared to 42.5% in
Lincoln County. The median age of arrestees
differed by 6 years in Somerset County (35 years
old) compared to Piscataquis County (29 years
old). Among the 16 counties, 15 reported more
opioid arrests than stimulant arrests. Counties
with the greatest percentage of arrests involving
opioids were Knox County (57.0%), Waldo County
(56.8%), Kennebec County (55.9%), and Hancock
County (55.6%). Stimulants accounted for fewer
than one-eighth of arrests (11.7%) in Waldo and
Lincoln Counties versus almost two-fifths (38.7%)
in Aroostook County. Schedule II substances
(e.g., cocaine) were most common in 13 (81.25%)
counties. State agencies were responsible for most
arrests in more than half (56.3%) of the counties
(Table 1).
DEA’s Automated Reports and Consolidated
Orders System
Medical distribution of opioids, as defined by MME,
increased in 2008 (2944.8 kg), peaked in 2010
(3207.5 kg), and declined through 2017 (2236.0
kg). A steep decline occurred from 2016 to 2017.
Opioids primarily used for pain accounted for onethird of the total MME distributed in Maine in 2008
(32.4%). Distribution of analgesic opioids increased
to 36.5% in 2012 before receding to 26.2% in 2017
(Figure 1, Panel A).
Figure 1, Panel B shows the dynamic changes in
the distribution of individual opioids standardized
to MME. Except for buprenorphine distribution,
which doubled between 2008 and 2017, all
other prescription opioids decreased over time.
Relative to their peak years over the past decade,
hydromorphone, methadone, codeine, oxycodone,
and morphine have undergone moderate reductions
in distribution. Oxymorphone, tapentadol, fentanyl,
hydrocodone, and meperidine had large reductions.
Lisdexamfetamine distribution increased 6.9-fold
between 2008 and 2017 (9.8 kg). Figure 1, Panel C
shows changes in other opioids during this period.
Methylphenidate distribution had a small (-10.1%)
decline since peaking in 2012 (157.0 kg) (Figure
1, Panel D). Amphetamine distribution greatly
increased (+67.9%) between 2008 and 2017 (54.0
to 90.7 kg). Pentobarbital distribution remained
relatively constant over the decade (79.9 kg in 2008
and 80.9 kg in 2017) (data not shown), whereas
3
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Table 1. Maine Diversion Alert Program Arrests from June 2013 to March 2018

Median
age, y

% Total
arrests
involving
opioids

% Total
arrests
involving
stimulants

Most
common
federal
class

Most
common
arresting
agency

35.2

31

42.1

35.9

2

Local

22.7

31.6

31

57

17.9

2

State

289 361

21.8

28.8

31

35.1

25.8

2

Local

693

68 824

21.2

27.9

31

27.6

38.7

2

State

Washington 313

31 625

20.8

41.9

35

47.3

18.9

2

Local

Lincoln

315

33 969

19.5

42.5

32

46

11.7

2

State

Penobscot

1400

152 692

19.3

29.5

31

44.7

29.6

2

Local

Waldo

352

39 155

18.9

32.4

31

56.8

11.7

2

State

Kennebec

932

119 980

16.4

35.6

31

55.9

24.7

1

Local

Hancock

417

54 659

16.1

35.7

32

55.6

20.4

2

State

Sagadahoc

210

35 113

12.6

28.1

32

42.4

17.6

1

State

Oxford

323

57 202

11.9

33.7

32

48.9

21.7

2

State

Somerset

285

50 745

11.8

25.6

35

51.2

27

2

Local

York

1038

201 169

10.9

32.5

31

54

22.5

1

State

Franklin

115

30 072

8.1

35.7

30

37.4

22.6

2

State

Piscataquis

39

16 935

4.8

35.9

29

51.3

20.5

2

Local

Total
population
size (2015)

Rate per
10K

%
Female

Androscoggin 1372

107 233

26.9

Knox

39 855

Cumberland 3000
Aroostook

County

Number
of total
arrests
430

*Rate is the number of arrests per year divided by the population size in 2015 and multiplied by ten-thousand.
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Figure 1. Distribution of Opioid Use. (Panel A) Total morphine milligram equivalents (MME) per year
for opioids for pain (oxycodone, fentanyl, morphine, hydrocodone, hydromorphone, oxymorphone,
tapentadol, codeine, and meperidine), opioid use disorder (OUD; methadone and buprenorphine), and all
11 agents. (Panels B-D) Raw weights of the most common opioids (Panel B), other opioids (Panel C), and
stimulants and secobarbital (Panel D) as reported by the Drug Enforcement Administration’s Automated
Reports and Consolidated Orders System10 in Maine from 2008 to 2017. Percent change relative to the
peak year is shown in parentheses.

Published by MaineHealth Knowledge Connection, 2021
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secobarbital distribution precipitously decreased
from rare (109.9 g in 2008) to unavailable (0.0 g in
2016 and 2017).
Further analysis was completed on 11 opioids,
expressed as a percentage of the total MME, in
2017 by 3-digit zip code. This analysis revealed
pronounced geographical variations relative to
the location of methadone clinics (Figure 2).
Methadone was the predominant opioid statewide,
accounting for a 3-fold greater percentage of the
total relative to buprenorphine (Figure 2, Panel

A). Opioids used primarily for OUD accounted
for most opioids distributed in the Bar Harbor
(75.0%), Rockland (85.2%), and Bangor (87.4%)
zip codes, likely due to the presence of one or
more methadone treatment programs in Rockland
and Bangor. Methadone was responsible for onefifth or less of opioids in York (21.0%), Boothbay
Harbor (12.6%), and Presque Isle (8.6%) (Figure
2, Panel B). Zip-code level heterogeneities were
9.2-fold for methadone, 9.5-fold for morphine, 6.2fold for fentanyl, 5.7-fold for oxycodone, and 4.9-

Figure 2. Geographical Variation in Opioid Use in Maine in 2017. Statewide percentage of the total
morphine milligram equivalent by opioid is shown for the state overall (Panel A). The other category includes
tapentadol, meperidine, oxymorphone, and codeine.
Statewide percentage of the total morphine milligram equivalent for specific opioids according by 3-digit
zip codes (Panels B-F) are shown with color gradation reflecting the specific opioid noted. The location of
methadone clinics (labeled M) are shown, as reported to the Drug Enforcement Administration’s Automation
of Reports and Consolidated Orders System.¹⁰
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fold for buprenorphine. Hydrocodone accounted for
an 8-fold greater portion of the total in Presque Isle
(9.9%) relative to Portland (1.1%) (data not shown).

DISCUSSION
The first 2 objectives of this study were to examine
county and demographic differences in controlled
substance misuse in Maine. The rate of arrests
showed 6-fold differences based on county. Except
for Aroostook County, which was more impacted
by stimulants, the state was very homogeneous in
which drug class (opioids) was related to the most
arrests. Examining controlled substance distribution
over time revealed that prescription opioids peaked
in 2010 and subsequently declined, particularly in
2016 and 2017. This study also determined that
the geographical differences in which prescription
opioids were most common by MME was associated
with the location of methadone clinics. These
facilities were not distributed uniformly statewide,
as 25% of the state’s total were in Penobscot
County and 33% were in Cumberland County.13
This regional analysis extends our prior research
that emphasized broader state-level patterns.9
The DAP provided information that complemented
Prescription
Monitoring
Programs
(PMPs)
for patient care. However, the DAP was also
invaluable for research and could complement
other data sources, such as self-report from the
National Household Survey on Drug Use and
Health or Monitoring the Future, emergency room
reports, and drug seizures.12 A key theme in prior
reports was the substantial diversity of substances
implicated in arrests beyond the “usual suspects”
of heroin, oxycodone, hydrocodone, illicit fentanyl,
methamphetamine, and cocaine. Hundreds
of arrests were related to benzodiazepines
(eg, alprazolam, clonazepam), marijuana, and
miscellaneous prescription pharmaceuticals that
were non-controlled (eg, gabapentin, quetiapine).9
Our analysis revealed that almost 10-fold
more arrests involved buprenorphine (812)
than methadone (82). These data suggest the
need to improve supervision and monitoring of
prescribed buprenorphine, or the ongoing need
for more access to buprenorphine prescribers.
The disparity was striking given that, on an MME
basis, methadone was distributed statewide over
3-fold more than buprenorphine. However, these
data can be explained, in part, by considering the
distribution of methadone for patients with OUD.
Published by MaineHealth Knowledge Connection, 2021

Due to federal regulations, addiction medicine
providers typically dispense daily methadone doses
onsite at methadone clinics. To date, Maine has 12
methadone clinics in 9 counties.13 These clinics
contain providers who specialize in medically
treating patients with OUD, especially methadone,
and with providing counseling services.
A high rate of buprenorphine arrests may still be
surprising, given the drug’s pharmacology as a partial
mu-receptor agonist. Buprenorphine has a safety
profile that is considerably more favorable than that
of methadone: LD50 = 235 mg/kg (buprenorphine)
vs 23 mg/kg (methadone) when given intravenously
in rats.14 Yet, 11 000 poison-control reports still
involved buprenorphine, primarily as a monotherapy
product, among children and adolescents (< 19
years old) from 2007 to 2016.15 Buprenorphine
was identified as a potentially contributing factor
in 22 drug deaths in Maine in 2017.16 In other
states, such as Wisconsin, law enforcement
identified an increased number of cases of driving
under the influence of buprenorphine, often with
benzodiazepines.17 Although both methadone and
buprenorphine are efficacious for OUD treatment,
the provision of methadone for OUD is considerably
more restricted than buprenorphine. A systematic
review identified better retention in OUD treatment
with methadone than buprenorphine/naloxone18,
however buprenorphine prescribing practices have
evolved significantly in the past decade. Methadone
accounted for one-eighth of the total opioid MME
in Presque Isle and Boothbay Harbor but threequarters in Bangor and Portland. Methadone
treatment programs in Maine increased from 9 in
2008 to 10 in 2017.10 Almost two-thirds of patients
in opioid treatment programs resided in only 3
counties (Penobscot County = 33%, Cumberland
County = 22%, and Washington County = 8%).19
Although there is room for improvement, Maine
ranked second in the United States for the most
waivered physicians for buprenorphine per capita.20
Pronounced reductions in opioid distribution over the
past decade have been reported.21 Perhaps, more
novel is the rate of change in opioid use, particularly
from 2015 to 2017. Liberal practices in prescribing
opioids during the 2000s was the unfortunate result
of a confluence of factors.7 We suspect that the
return to more judicious and evidence-based use
of opioids, particularly minimizing use in patients
with chronic non-cancer pain, may also reflect
the convergence of multiple policy and incentive
7
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changes at the federal, state, and local level. In
January 2017, Maine’s “An Act to Prevent Opiate
Abuse by Strengthening the Controlled Substances
Prescription Monitoring Program” took effect. This
act was unusual for a state prescribing law because
it included fiscal penalties for non-adherence. Maine
had a significantly greater decrease in prescription
opioids than several other New England (CT,
MA, RI, VT) and mid-Atlantic states (NY, PA) that
enacted similar opioid prescribing laws that lacked
penalties.21 In the year that followed, between 2017
and 2018, drug-related deaths involving prescription
opioids in Maine declined by 37%.16
Three other findings are noteworthy. The
substantial increase in lisdexamfetamine and other
amphetamine distribution extend earlier national
data.7 ARCOS, and DAP, do not provide information
about whether the original source of these stimulants
was for attention deficit hyperactivity disorder in
children or adults, obesity, post-traumatic brain
injury, or another indication. The ratio of males
to females for drug-related deaths in Maine was
2.51 to 1 in 20175 and 2.45 to 1 in 2018.16 Among
arrestees, the ratio was similar (2.14 to 1). Together
with other arrest data, these findings indicate that
sex differences in drug misuse may be gradually
declining.17
Some strengths and limitations of these datasets are
noteworthy. The DAP was unique to Maine and, to
our knowledge, has not been emulated elsewhere,
which precludes comparisons with other states.
Reporting to the DAP was voluntary, and some
agencies (eg, tribal police) infrequently submitted
arrest information, which is a caveat in interpreting
data in Table 1. Similarly, some individuals may have
been arrested multiple times over a 6-year period.
Although we cannot account for this factor in a deidentified research database, we do not believe
it would impact southern versus northern Maine
counties differently. It is important to emphasize
that there are key differences between an arrest
and a subsequent conviction, and data regarding
conviction is unknown. It is also unknown how
often field tests, whose specificity is questionable,
were used to determine the presumptive substance
identity.22 Finally, there is a potential for bias in DAP
regarding populations that are more likely to be
surveilled by law enforcement and subsequently
arrested, such as those with a history of opioid
overdose or diagnosed OUD. Socioeconomic
https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss2/2
DOI: 10.46804/2641-2225.1074

and racial disparities might also contribute to
bias. Unlike PMPs, ARCOS is comprehensive in
its coverage of Schedule II substances. ARCOS
reports by substance weight instead of using
perhaps more intuitive units of analysis, such as
prescriptions. Methadone was the most prevalent
opioid by MMEs.3,23 The 42 CFR Part 2 prevented
methadone, when used by methadone treatment
programs, from being entered into the state PMP
results. Although arguably well-intentioned, this
federal regulation is a key caveat when interpreting
other pharmacoepidemiological research,8,24 and
some have advocated that this regulation be
updated.25

CONCLUSIONS
The DAP was an important information-sharing and
pharmacoepidemiological resource that was unique
to Maine. This study identified a 6-fold difference
in arrest rates by county. There were also sizable
differences in drug arrests involving opioids and
stimulants by county. A better understanding of the
pronounced regional differences in prescription
drug distribution and arrests may improve targeted
public health interventions, including education and
access to treatment. We are cautiously optimistic
that the DAP could be integrated with PMPs and
implemented in other states. Continued monitoring
of trends in arrests, prescription use, and misuse is
warranted. Further, limiting access by adolescents
and persons with SUD to prescription opioid
analgesics and other misusable substances should
be a continued priority.
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